Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1973 1
1999 1
2004 1
2010 1
2021 1
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

5 results

Results by year

Filters applied: . Clear all
Page 1
[S.M. Lejtes 1899-1972].
Korec R. Korec R. Cesk Patol. 1973 Aug;9(3):168. Cesk Patol. 1973. PMID: 4583560 Slovak. No abstract available.
AmpC- and Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae Detected in Fresh Produce in Central Ohio.
Parker E, Albers A, Mollenkopf D, Korec D, Mathys D, Stuever D, Wittum T. Parker E, et al. J Food Prot. 2021 May 1;84(5):920-925. doi: 10.4315/JFP-20-347. J Food Prot. 2021. PMID: 33428740 Free article.
Using selective media, we found 23 (6.3%) samples that produced Enterobacteriaceae expressing an AmpC beta-lactamase phenotype, with 11 (3.0%) confirmed to contain blaCMY and 6 (1.6%) that produced Enterobacteriaceae with an extended-spectrum beta-lactamase (ESBL) phenotype, 1 (0 …
Using selective media, we found 23 (6.3%) samples that produced Enterobacteriaceae expressing an AmpC beta-lactamase phenotype, with 11 (3.0 …
Topoisomerase-II alpha expression as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel.
Durbecq V, Paesmans M, Cardoso F, Desmedt C, Di Leo A, Chan S, Friedrichs K, Pinter T, Van Belle S, Murray E, Bodrogi I, Walpole E, Lesperance B, Korec S, Crown J, Simmonds P, Perren TJ, Leroy JY, Rouas G, Sotiriou C, Piccart M, Larsimont D. Durbecq V, et al. Mol Cancer Ther. 2004 Oct;3(10):1207-14. Mol Cancer Ther. 2004. PMID: 15486187 Clinical Trial.
EXPERIMENTAL DESIGN: Primary tumor samples from patients enrolled in a randomized, phase III clinical trial comparing single-agent doxorubicin (75 mg/m(2) q3wks) with docetaxel (100 mg/m(2) q3wks) were collected and topo-II status was evaluated by immunohistochemist …
EXPERIMENTAL DESIGN: Primary tumor samples from patients enrolled in a randomized, phase III clinical trial comparing single-agent doxorubic …
Estimation of muscle response using three-dimensional musculoskeletal models before impact situation: a simulation study.
Bae TS, Loan P, Choi K, Hong D, Mun MS. Bae TS, et al. J Biomech Eng. 2010 Dec;132(12):121011. doi: 10.1115/1.4002795. J Biomech Eng. 2010. PMID: 21142325
For low-speed sled-impact crash, experiment and simulation with optimized and unoptimized muscle parameters were performed at 9.4 m/h and 10 m/h and muscle activities were compared among them. The muscle activities with optimized parameters were closer to experiment …
For low-speed sled-impact crash, experiment and simulation with optimized and unoptimized muscle parameters were performed at 9.4 m/h …
Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer.
Chan S, Friedrichs K, Noel D, Pintér T, Van Belle S, Vorobiof D, Duarte R, Gil Gil M, Bodrogi I, Murray E, Yelle L, von Minckwitz G, Korec S, Simmonds P, Buzzi F, González Mancha R, Richardson G, Walpole E, Ronzoni M, Murawsky M, Alakl M, Riva A, Crown J; 303 Study Group. Chan S, et al. J Clin Oncol. 1999 Aug;17(8):2341-54. doi: 10.1200/JCO.1999.17.8.2341. J Clin Oncol. 1999. PMID: 10561296 Clinical Trial.
PATIENTS AND METHODS: Patients were randomized to receive an intravenous infusion of docetaxel 100 mg/m(2) or doxorubicin 75 mg/m(2) every 3 weeks for a maximum of seven treatment cycles. ...
PATIENTS AND METHODS: Patients were randomized to receive an intravenous infusion of docetaxel 100 mg/m(2) or doxorubicin 75 mg/m …